Background Oxaliplatin-based adjuvant therapy is the standard of care for stage III colon cancer. Adjuvant capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin has not been directly compared; therefore, we aimed to analyse the effi cacy and safety of these treatments using individual patient data pooled from four randomised controlled trials. We also assessed post-relapse survival, which has been postulated to be worse in patients receiving adjuvant oxaliplatin.
Introduction
Adjuvant treatment with a fl uoropyrimidine plus oxaliplatin is the standard of care for resected stage III colon cancer, 1, 2 as supported by the results of three randomised controlled trials. [3] [4] [5] [6] [7] Oxaliplatin plus infusional leucovorin and fl uorouracil (FOLFOX) signifi cantly increased disease-free survival and overall survival compared with leucovorin and fl uorouracil alone in the MOSAIC trial. 3, 4 Oxaliplatin plus bolus leucovorin and fl uorouracil (FLOX) signifi cantly increased disease-free survival compared with leucovorin and fl uorouracil alone in the NSABP C-07 trial, albeit with no signifi cant overall survival diff erence at 8 years' follow-up. 5, 6 Oxaliplatin plus oral capecitabine (Xeloda, F Hoff mann-La Roche, Basel, Switzerland) (XELOX) signifi cantly increased diseasefree survival and overall survival compared with bolus leucovorin and fl uorouracil in the XELOXA trial. 7 Singleagent leucovorin and fl uorouracil or capecitabine is also recommended in patients for whom oxaliplatin is unsuitable; 1 in the non-inferiority X-ACT trial, capecitabine was shown to be as effi cacious as leucovorin and fl uorouracil. 8, 9 Despite these results, data from the NSABP C-07 and MOSAIC trials-which both included patients with stage II or III disease-suggested that adjuvant oxaliplatin might reduce post-relapse survival. 4, 10 No direct comparisons of capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin have been done in the adjuvant setting, and such a study is unlikely because treatment patterns are now well established. However, use of XELOX and FOLFOX in both the fi rst-line and secondline treatment of metastatic colorectal cancer have led to similar survival outcomes. [11] [12] [13] In the absence of randomised controlled trials addressing the comparative effi cacy of adjuvant oxaliplatin combined with capecitabine or leucovorin and fl uorouracil, and to further assess the eff ect of oxaliplatin on post-relapse survival, we compared the effi cacy and safety of adjuvant capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin for resected stage III colon cancer by pooling individual patient data from four large, randomised controlled phase 3 trials: NSABP C-08, XELOXA, X-ACT, and AVANT. These trials were selected on the basis of access to the complete clinical datasets, which enabled the use of individual patient data to address relevant scientifi c questions.
We postulated that effi cacy outcomes (disease-free survival, relapse-free survival, and overall survival) would be the same with capecitabine-based and leucovorin and fl uorouracil-based regimens, but that post-relapse survival would be reduced in patients receiving adjuvant oxaliplatin.
Methods

Study design and participants
The designs and patient eligibility criteria of these four studies have been reported previously. 7, 8, 14, 15 Further details are provided in appendix pp 1-2. Patients with stage II colon cancer were excluded from this comparison of the standards of care for stage III disease. Tumour stage was recorded variably across the studies; therefore, for this analysis, stage was derived from existing tumour-nodemetastasis (TNM) staging information, based on the American Joint Committee on Cancer (7th edition) defi nition of stage III colon cancer as any stage T, and nodal stage N1 or N2. 16 Patients receiving bevacizumab in AVANT and NSABP C-08 were excluded from the primary analysis because its effi cacy has not been demonstrated in this setting. 14, 15 However, selected posthoc sensitivity analyses were done on the complete dataset of patients with stage III disease, and these included patients who received bevacizumab.
Disease-free survival, relapse-free survival, and overall survival were compared according to the fl uoropyrimidine received-ie, capecitabine or XELOX (capecitabine with or without oxaliplatin) compared with leucovorin and fl uorouracil, FOLFOX-4, or mFOLFOX-6 (leucovorin and fl uorouracil with or without oxaliplatin). To assess the eff ect of oxaliplatin when combined with capecitabine, we compared outcomes between patients treated with XELOX versus capecitabine monotherapy.
We assessed the eff ect of oxaliplatin on post-relapse survival by comparing outcomes between the combined XELOX and FOLFOX groups and those who received leucovorin and fl uorouracil monotherapy. The capecitabine and leucovorin and fl uorouracil groups in X-ACT were not pooled because of potential diff erences in effi cacy when these drugs are given as single agents in the adjuvant setting, based on a pre-planned multivariable analysis. 9 All studies were done in accordance with the Declaration of Helsinki and investigations were undertaken after approval from local ethics committees or institutional review boards, as appropriate. All patients provided written informed consent.
Outcomes
The primary endpoint was disease-free survival, which was defi ned as the date of randomisation to the date of disease recurrence, new occurrence of colon cancer, or death from any cause. Secondary endpoints were relapse-free survival (defi ned in the same way as disease-free survival, but excluded deaths unrelated to treatment or colon cancer), overall survival (time from randomisation to the date of death, irrespective of the cause), and post-relapse survival (time from disease recurrence [relapse] until death from any cause; assessed only in patients who relapsed).
In the XELOXA and AVANT trials, the type of diseasefree survival event (recurrence, new colon cancer, or death) was recorded, enabling direct identifi cation of relapses. Because the defi nitions of disease-free survival diff ered between XELOXA and AVANT versus X-ACT and NSABP C-08, patients were identifi ed as relapsing if a disease-free survival event occurred along with a censored death variable or death recorded at a subsequent date. Based on the defi nition of disease-free survival used in trials for the assigned treatment, the defi nition included new colon cancer and relapse. This rule was used to identify patients' distant (metastatic) relapses relevant to the scientifi c issue addressed by the analysis. In X-ACT and NSABP C-08, the types of disease-free survival event were not reported; hence, in order to replicate the identifi cation process for patients with distant relapse in these trials, a disease-free survival event along with either a censored death or subsequent death would essentially identify which patients should be included the post-relapse survival analysis. This approach allowed for uniform identifi cation of patients with distant relapse across trials. Post-relapse survival duration was then established as the time from relapse date until death or date last known to be alive.
For effi cacy assessments, patients who did not have an event at the time of the trial database cutoff were censored on the date at which they were last known to be event-free. Time from surgery to relapse (years) In all four trials, adverse events were monitored during treatment and for 28 days after the fi nal dose of study drug. All adverse events were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 13.1 and allocated a severity grade of 1-4 (mild, moderate, severe, or life-threatening or fatal). More than one occurrence of the same adverse event in the same patient was recorded as a single event at the greatest severity recorded. Incidences of serious adverse events were also observed. Since serious adverse events were not fl agged in NSABP C-08, adverse events occurring during that study were recorded as serious if they were fatal or submitted to the Adverse Event Expedited Reporting System (AdEERS).
Data about treatments after relapse were collected for patients in X-ACT, XELOXA, and AVANT.
Statistical analyses
For each time-to-event assessment, we undertook Kaplan-Meier survival analyses and compared these using the log-rank test. We did assessments according to assigned treatment. We estimated hazard ratios (HRs) and associated 95% CIs using univariable Cox regression, and we used the Wald test in each subgroup to test its diff erence from the null value of 1. The same approach assessed treatment eff ects in subgroups stratifi ed by sex, age (<70 years or ≥70 years), T stage (T1-2 or T3-4), and N stage (N1 or N2).
We used multiple Cox proportional hazards regression to test for independent eff ects of oxaliplatin after controlling for sex, age, T stage, and N stage. To assess whether the incremental eff ects caused by oxaliplatin were similar, irrespective of the fl uoropyrimidine backbone, the oxaliplatin (yes/no) × fl uoropyrimidine (leucovorin and fl uorouracil or capecitabine) term was included in the model as a predictor and tested for signifi cance. Additional covariables were considered but were removed from the fi nal model, including colon cancer stage (IIIA or IIIB/C), number of positive lymph nodes (≤3 or >3), medical comorbidity measures (adapted Charlson Comorbidity Index/National Cancer Institute Combined Index), Eastern Cooperative Oncology Group Performance Status, and race. To focus the present analysis solely on patients with stage III colon cancer, the only patients from the four trials not included were those with stage II disease in NSABP C-08 (n=322) and in AVANT (n=584). As surgical, medical, and staging standards changed, and biological agents associated with survival benefi t were introduced for metastatic disease during the course of the trials, we did sensitivity analyses to assess the potential eff ects of these changes. We also assessed surgical quality and staging by number of lymph nodes examined to control for patients enrolled in X-ACT in which this information was not collected. Date of randomisation (before 2004 or 2004 or later) was included to assess the eff ects of new treatments. Additionally, we did a direct comparison of XELOX versus FOLFOX in the full analytic cohort, adjusting for exposure to bevacizumab to supplement the assessment of oxaliplatin treatment eff ect.
Adjusted survival curves were created using the average covariate and corrected group prognosis methods; 17,18 the latter approach is viewed as an improvement over the Relapse-free survival 0·99 (0·89-1·10) 0·85
Overall survival 1·12 (0·97-1·28) 0·11
XELOX* versus capecitabine monotherapy
Disease-free survival 0·74 (0·64-0·86) <0·0001
Relapse-free survival 0·73 (0·63-0·85) <0·0001
Overall survival 0·75 (0·63-0·88) 0·0007
XELOX=capecitabine plus oxaliplatin. FOLFOX=leucovorin and fl uorouracil plus oxaliplatin. *Adjusted for use of bevacizumab. former because it derives the adjusted survival curve using a weighted average of the individual survival curves, calculated using a fi tted Cox regression model. The weights used are proportional to the number of individuals at each level of the covariates in the entire sample at baseline. In the XELOX or FOLFOX group, post-relapse survival was also compared between patients with documented use of therapies other than oxaliplatin after relapse and those who received oxaliplatin post relapse. SAS version 8.2 was used for all statistical analyses. The four randomised controlled trials are registered with ClinicalTrials.gov, numbers NCT00009737, NCT00069121, NCT00096278, and NCT00112918.
Role of the funding source
F Hoff mann-La Roche and Genentech Inc, in conjunction with the authors, were involved in the analyses, data interpretation, and the decision to submit for publication. H-JS and CT had full access to all the study data and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the compositions of the pooled analysis groups with respect to the individual trials. Baseline demographics and disease characteristics were, in general, balanced across the groups (table 1) . The X-ACT trial did not gather data about numbers of examined lymph nodes, which resulted in a greater proportion of patients who received capecitabine with or without oxaliplatin with "unknown" number of nodes examined. Therefore, sensitivity analyses were done in patient subgroups with up to 12 and more than 12 nodes assessed. The median duration of follow-up was longer in XELOXA (84 months) and X-ACT (74 months) than in NSABP C-08 (36 months) and AVANT (50 months). 
Results
D
For our comparison of the effi cacy of capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin, a total of 5819 patients were included in the primary analyses. Three patients receiving mFOLFOX-6 in the NSABP C-08 trial did not have the required information for stage derivation and were therefore excluded. In our analysis, median follow-up was 44 months (IQR 33-69 months) for leucovorin and fl uorouracil with or without oxaliplatin, and 74 months (46-84 months) for capecitabine with or without oxaliplatin.
At 5 years' follow-up, 62·8% of patients in both groups were alive and disease free. The adjusted disease-free survival hazard ratio (HR) was 1·02 (0·93-1·11; p=0·72) (fi gure 2A). The unadjusted disease-free survival analysis (HR 1·01 [95% CI 0·92-1·10]; p=0·86) was consistent with the adjusted analysis, with the survival curves being almost identical.
5-year relapse-free survival was 64·6% for patients in the capecitabine with or without oxaliplatin group and 64·7% for leucovorin and fl uorouracil with or without oxaliplatin group. The adjusted 5-year relapse-free HR was 1·02 (0·93-1·12; p=0·72) (appendix p 3). As was the case for disease-free survival, the unadjusted 5-year relapse-free survival analysis (HR 1·01 [95% CI 0·92-1·11]; p=0·86) was consistent with the adjusted analysis, and the survival curves were similar.
5-year overall survival rates were 73·9% for patients in the capecitabine with or without oxaliplatin group and 75·2% for the leucovorin and fl uorouracil with or without oxaliplatin group. The adjusted HR was 1·04 (95% CI 0·93-1·15; p=0·50) (fi gure 2B). Again, the unadjusted analysis was consistent with the adjusted analysis (HR 1·02 [95% CI 0·92-1·14]; p=0·65), and the survival curves were similar.
Sensitivity analyses showed consistent results between patients with up to 12 and more than 12 lymph nodes studied for disease-free, relapse-free, and overall survival (appendix p 4), and were consistent and similar to those in the primary analysis when the patients who were treated with bevacizumab were included (ie, total N=8734; table 2) or when the analysis was adjusted for study entry date (appendix p 5).
Despite the oxaliplatin-by-fl uoropyrimidine interactions not being signifi cant at the 0·05 level for disease-free survival (p=0·17) or relapse-free survival (p=0·15; data not shown), the eff ects of oxaliplatin were estimated for the respective fl uoropyrimidines. According to Cox regression modelling, the estimated disease-free survival HR for the eff ect of oxaliplatin was 0·75 (95% CI 0·60-0·93) with capecitabine and 0·70 (0·59-0·82) with leucovorin and fl uorouracil. Further analyses that included additional covariables (study entry date [2004 or later vs before 2004]), and bevacizumab use [yes vs no]) showed a lessened degree of interaction (data not shown). HRs for relapse-free survival for capecitabine with or without oxaliplatin were 0·73 (95% CI 0·63-0·85) compared with leucovorin and fl uorouracil with or without oxaliplatin 0·64 (0·57-0·71).
For overall survival, the multiple Cox regression analysis of the oxaliplatin-by-fl uoropyrimidine inter action was signifi cant (p=0·014). Therefore, the eff ects of oxaliplatin when used in combination with either capecitabine or leucovorin and fl uorouracil were estimated in the same Cox regression analysis. The estimated HR for oxaliplatin was 0·75 (95% CI 0·63-0·88) with capecitabine, and 0·56 (0·48-0·65) with leucovorin and fl uorouracil. Although the incremental benefi t was slightly reduced with capecitabine versus leucovorin and fl uorouracil, direct comparison of survival outcomes between XELOX-treated and FOLFOX-treated patients (adjusted for use of bevacizumab) showed that these did not diff er signifi cantly (table 2, appendix p 5), and 5-year disease-free survival (68·2% for XELOX and 66·6% for FOLFOX), relapse-free survival (70·1% and 68·4%), and overall survival (78·7% and 79·6%) were similar ( (table 5) . Adjusted survival curves generated using either the average covariate (fi gure 3B) or the corrected group prognosis method (fi gure 3C) support these results. Figure 3D shows the unadjusted Kaplan-Meier plots for the N1 and N2 subgroups from the XELOX or FOLFOX versus leucovorin and fl uorouracil comparison.
Adjusted analyses also showed that post-relapse survival was signifi cantly longer for patients younger than 70 years than for those aged 70 years or older (table 5) . In unadjusted analyses, the diff erence in postrelapse survival for stage N1 compared with stage N2 disease was consistent in the subgroups of patients with more than 12 nodes (HR 0·70 [95% CI 0·56-0·86]; p=0·0009) and 12 or fewer nodes examined (0·71 [0·56-0·89]; p=0·003).
As our next assessment of post-relapse survival, we compared this outcome in patients who received regimens containing capecitabine versus those containing fl uorouracil. The analysis population comprised 659 patients who relapsed after receiving adjuvant capecitabine with or without oxaliplatin and 1222 patients who relapsed after receiving leucovorin and fl uorouracil with or without oxaliplatin. Median follow-up for this analysis was 44 months (IQR 33-69 months) for leucovorin and fl uorouracil with or without oxaliplatin, and 74 months (46-84 months) for capecitabine with or without oxaliplatin. Unadjusted Kaplan-Meier analysis (appendix p 6) showed that post-relapse survival was similar between the groups (HR 1·07 [95% CI 0·95-1·20]; p=0·26). Adjusted survival curves generated with use of either the average covariate or the corrected group prognosis method support these results (data not shown). Adjusted analyses again showed signifi cantly longer post-relapse survival for patients aged younger than 70 years than for those aged 70 years and older (HR 0·72 [95% CI 0·63-0·83]; p=0·0001) and for stage N1 versus N2 disease (HR 0·75 [0·67-0·84]; p=0·0001).
In sensitivity analyses, post-relapse survival was similar between patients who received capecitabine and those who received XELOX (appendix p 7) (HR 0·94 [95% CI 0·78-1·13]; p=0·50)-confi rming our pooling of patients treated with capecitabine with those treated with XELOX for our primary analyses-and for patients treated with capecitabine or leucovorin and fl uorouracil monotherapy.
Patients who relapsed after less than 1 year had worse post-relapse survival than did those relapsing later in the overall population. However, we recorded no diff erence in post-relapse survival between the leucovorin and fl uorouracil and oxaliplatin-based treatment groups when comparing patients with less than 1 year or 1 year or longer between surgery and relapse (appendix p 8). Table 6 summarises post-relapse therapies in patients who relapsed (excluding participants from NSABP C-08, from whom data were not collected). In patients who received adjuvant XELOX or FOLFOX, no signifi cant diff erence was recorded in post-relapse survival associated with the documented use of non-oxaliplatin therapies after relapse compared with those who received oxaliplatin after relapse (HR 1·03 [95% CI 0·77-1·38]; p=0·85).
Discussion
Our analysis has shown that combination therapy with oxaliplatin for stage III colon cancer provides consistently improved outcomes, irrespective of the fl uoropyrimidine backbone (capecitabine or leucovorin and fl uorouracil), and that the benefi t of combining oxaliplatin with a fl uoropyrimidine is not compromised by decreased survival following relapse. These data also suggest that the type of previous adjuvant therapy need not be a stratifi cation factor for trials in metastatic colorectal cancer. This analysis used pooled individual patient data from four large randomised controlled trials, which is to our knowledge the largest population of oxaliplatin-treated patients with stage III colon cancer studied so far (panel). This large population gave suffi cient statistical power to record diff erences that it would not have been possible to detect in the individual trials. All four trials were well conducted, and were of uniform data quality, which allowed the data to be pooled. The trials also assessed regimens that are used frequently in clinical practice and are endorsed in clinical practice guidelines (leucovorin and fl uorouracil, capecitabine, FOLFOX, and XELOX). The NSABP C-07 and MOSAIC trials were both excluded, mainly because they generated one of the hypotheses we wanted to test-namely, that adjuvant oxaliplatin might adversely aff ect post-relapse survival. Additionally, FLOX (which was assessed in NSABP C-07) is not used often, because it has both an unfavourable safety profi le and no proven overall survival benefi t.
The present analysis supports equivalent effi cacy of XELOX and FOLFOX in the adjuvant setting. However, a signifi cant oxaliplatin-by-fl uoropyrimidine interaction for overall survival suggested that the relative contribution of oxaliplatin to this outcome diff ered depending on fl uoropyrimidine choice. Consistent with this fi nding, individual HRs showed a slightly greater incremental benefi t for oxaliplatin when combined with leucovorin and fl uorouracil than when combined with capecitabine. These observations are likely related to the evolving standards between 1998 and 2007 when these studies accrued, with increased attention paid to the quality of surgery and staging, improved understanding of the importance of receiving all active agents in the metastatic setting, and the introduction of new agents with proven eff ects on overall survival in the metastatic setting, eg bevacizumab. [19] [20] [21] Sensitivity analyses consistently showed improved outcomes (in disease-free, relapse-free, and overall survival) in patients randomly allocated to treatment groups in 2004 or later compared with those randomised before 2004. Owing to a desire to create a study population that was as homogeneous as possible, we excluded patients receiving XELOX in combination with bevacizumab from our primary analysis. This approach created an imbalance between the XELOX and FOLFOX analytic cohorts: most XELOX patients were recruited before 2004, whereas the entire FOLFOX population was recruited during or after 2004. When primary analyses were repeated on the entire stage III cohort, adjusted for use of bevacizumab, these diff erences were no longer statistically signifi cant, and 3-year, 4-year, and 5-year disease-free, relapse-free, and overall survival rates were equivalent. This fi nding suggests that the observations made in the primary analyses were largely associated with this imbalance. It should also be noted that 5-year diseasefree and overall survival outcomes are consistent with those reported in published studies for patients with stage III colon cancer who received oxaliplatin-based therapy. 4, 6 The present analysis also showed signifi cantly improved outcomes with XELOX versus capecitabine monotherapy. Since these two regimens have not been directly compared in a randomised trial, this is a salient fi nding that supports the use of XELOX in patients for whom combination therapy is appropriate.
The fi nding that post-relapse survival is not aff ected by previous use of oxaliplatin-containing adjuvant regimens is consistent with the established benefi ts of XELOX and FOLFOX, which signifi cantly increase disease-free survival and overall survival compared with leucovorin and fl uorouracil monotherapy. 3, 4, 7 We found no evidence that suggested that the disease-free survival benefi t of XELOX or FOLFOX is attenuated by shortened survival following recurrence; this result contrasts with those of the MOSAIC and NSABP C-07 trials. In MOSAIC, median post-relapse survival seemed to be shorter in patients randomly allocated to FOLFOX (21 months) compared with those assigned to bolus plus infusional leucovorin and fl uorouracil (24 months), although no statistical comparison was done. 3 In NSABP C-07, post-relapse survival was signifi cantly shorter in patients with stage II and III colon cancer randomly assigned to FLOX compared with those assigned to bolus leucovorin and fl uorouracil (HR 1·20 [95% CI 1·00-1·43]; p=0·0497); 10 this fi nding might account for the improvement in overall survival with FLOX failing to reach statistical signifi cance, despite a clear increase in disease-free survival. 6 The reason for these apparent discrepancies in relation to the eff ect of adjuvant oxaliplatin on post-relapse survival is unclear. MOSAIC and NSABP C-07 post-relapse survival data have been reported only for the overall population of patients with both stage II and stage III disease. 3, 5 By contrast, the present analysis focused solely on patients with stage III colon cancer. Similarly, leucovorin and fl uorouracil were administered via diff erent bolus or infusion regimens; however, this diff erence is unlikely to be important, since similar survival outcomes were shown with infusional and bolus intravenous fl uoropyrimidine regimens in the GERCOR C96.1 trial. 22 Moreover, there were also diff erences between the oxaliplatin-containing regimens: FOLFOX and XELOX in the present analysis and FLOX in NSABP C-07. We also cannot exclude diff erences in post-relapse therapy, but given the similarity in patient populations and timing of the studies, again major diff erences are unlikely. Finally, diff erences between the study populations in other prognostic or predictive molecular biomarkers 23 are unlikely but cannot be excluded. However, how these diff erences in patient populations and treatment might account for the apparent discrepancy with respect to post-relapse survival remains unclear. The two earlier studies that reported an adverse eff ect of adjuvant oxaliplatin on survival if patients relapse 3, 10 did not have a suffi cient number of events for a robust analysis, whereas the present analysis is suffi ciently large to indicate this was most likely a chance fi nding and unlikely to be a true eff ect.
Previous results from the Adjuvant Colon Cancer End Points (ACCENT) project showed poorer post-relapse survival with node-positive versus node-negative disease in patients treated with fl uorouracil-based adjuvant therapy or surgery alone. 24 These fi ndings are extended here by showing that, in node-positive stage III disease, a greater extent of nodal involvement (N2 vs N1) is prognostic for poorer post-relapse survival in patients receiving either oxaliplatin combinations or single-agent leucovorin and fl uorouracil as adjuvant therapy. This suggests that both reduced disease-free and post-relapse survival might contribute to the reduction in overall survival that is associated with higher N stage. 25 Greater baseline nodal involvement at diagnosis could well be associated with a more aggressive disease phenotype, and identifi cation of the disease later in its natural history.
The observation that patients aged 70 years and older have worse post-relapse survival is again consistent with the initial ACCENT data, which show signifi cantly shorter survival after recurrence with advancing age in patients with stage II and III colon cancer treated with fl uorouracil-based adjuvant therapy. 24 Along with the proportional increase in deaths from competing causes in older patients compared with younger individuals, a diminished functional reserve and accumulating comorbidity with age might limit delivery of otherwise optimum post-relapse therapy, thereby aff ecting postrelapse survival. 26 The similar post-relapse survival recorded with capecitabine with or without oxaliplatin and leucovorin and fl uorouracil with or without oxaliplatin adds to the large body of evidence showing at least equivalent outcomes between these two fl uoropyrimidines in a range of settings. 8, [11] [12] [13] 15 In terms of tolerability and safety, capecitabine-based treatment showed a favourable adverse event profi le over leucovorin and fl uorouracil-based regimens, with lower numbers of oxaliplatin-related grade 3-4 events (neuropathy, neutropenia, and febrile neutropenia) and overall grade 3-4 events, although grade 3 hand-foot syndrome was more frequent with capecitabine than with leucovorin and fl uorouracil. This fi nding is not unexpected in view of the better safety profi le of capecitabine monotherapy over bolus leucovorin and fl uorouracil reported in X-ACT. 8 Similar adverse event profi les of XELOX and FOLFOX in patients with metastatic colorectal cancer have been reported. [11] [12] [13] One of the aims of the IDEA collaboration 27 -a prospective combined analysis of phase 3 trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX-4 or mFOLFOX-6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer-is to reduce toxicities of oxaliplatin-based adjuvant therapy for stage III colon cancer, and results are eagerly anticipated.
Since this was a pooled analysis, the results are subject to the limitations of the original data sources. Duration of follow-up was imbalanced, and X-ACT did not provide numbers of lymph nodes assessed. However, sensitivity analyses suggested that the number of lymph nodes assessed was not a confounding factor. Access to data from one important trial (MOSAIC) was not possible. In current clinical practice, leucovorin and fl uorouracil is often administered as a continuous infusion since this has been associated with improved tolerability compared with bolus administration, 22, [28] [29] [30] but the leucovorin and fl uorouracil monotherapy was administered as a bolus in the studies analysed, which was the standard of care when X-ACT and XELOXA were designed. Nonetheless, bolus leucovorin and fl uorouracil versus bolus plus infusional leucovorin and fl uorouracil show similar effi cacy in trials of adjuvant therapy, 22 which means that bolus leucovorin and fl uorouracil is a reasonable comparator.
The main strengths of the dataset and analyses include the large patient population, high data quality, availability of patient-level data, and extended duration of follow-up of patients in the patient pool, which ensured that more than a third of patients in each group had experienced a disease-free survival event at data cutoff . The individual patient data approach allowed for adjustment with use of patient-level covariates to produce treatment eff ects with better precision. As such, power for comparisons of estimated treatment eff ects was increased, which also allowed us to address issues that were not the focus of the individual trials.
Panel: Research in context
Systematic review Adjuvant therapy with oxaliplatin plus either intravenous leucovorin and fl uorouracil or oral capecitabine is the standard of care for stage III colon cancer, and fl uoropyrimidine monotherapy is recommended for some patients. No randomised studies have directly compared capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin in this setting. Therefore, we assessed the effi cacy and safety of capecitabine with or without oxaliplatin versus leucovorin and fl uorouracil with or without oxaliplatin using data pooled from four randomised controlled trials, which were selected on the basis of availability of access to complete patient-level data.
Interpretation
Combination therapy with oxaliplatin for stage III colon cancer provides consistently improved outcomes, irrespective of the fl uoropyrimidine backbone (capecitabine or leucovorin and fl uorouracil), and the benefi t of combining oxaliplatin with a fl uoropyrimidine is not compromised by decreased survival following relapse. These data also suggest that the type of previous adjuvant therapy need not be a stratifi cation factor for trials in metastatic colorectal cancer. These data add to the evidence that oxaliplatin plus capecitabine or leucovorin and fl uorouracil is the standard of care for the adjuvant treatment of stage III colon cancer, off ering physicians fl exibility to treat patients according to the patients' overall physical performance and preference.
